Hikma has made no secret of its lowered expectations for its generics business in 2022. Having downgraded its forecasts multiple times over the course of last year (Also see "Hikma Eyes Return To Growth After Further Cutting Generics Forecasts" - Generics Bulletin, 4 August, 2022.), the firm has prepared investors and analysts for a rocky 12-month report.
And now, publishing its annual results, the company has confirmed that it has seen “a tough year for this business,...






